StockData
Personalis, Inc. logo

Personalis, Inc. (PSNL) company profile

PSNLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30344% above fair value
$14.80+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.58BP/E –Yield –

About Personalis

Services-Medical Laboratories, SIC 8071

Personalis, Inc. operates as a cancer genomics company focused on enabling personalized cancer therapies and providing diagnostic testing solutions. The company offers specialized laboratory testing services that support clinical diagnostics and pharmaceutical research and development, including population sequencing and enterprise sales. Its service offerings assist biopharmaceutical and clinical diagnostic partners in advancing cancer therapeutics, monitoring disease progression, and supporting clinical trials. Key customers include biopharmaceutical organizations such as Moderna, Pfizer, and Merck, along with healthcare entities like AstraZeneca and government initiatives such as the U.S. Department of Veterans Affairs' Million Veteran Program.

The company operates primarily through a single consolidated headquarters and laboratory facility located in the United States, alongside an international presence via its subsidiary in the United Kingdom. Operations, sales, and research activities are supported through domestic facilities and commercial partnerships spanning global jurisdictions. Personalis maintains its corporate headquarters and primary laboratory operations in Fremont, California.

Summary of the business section of Personalis's latest annual report, written by StockData.

Company profile

Company

Legal name
Personalis, Inc.
Founded
2011
Headquarters
Fremont, CA
Address
6600 Dumbarton Circle 94555
Phone
(650) 752-1300
Employees
260, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Jose, California

Stock & identifiers

Ticker
PSNL
Exchange
Nasdaq
IPO date
Jun 20, 2019
Shares outstanding
107M, Jul 29, 2026
Public float
$578.18M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1527753
CUSIP
71535D106
ISIN
US71535D1063
FIGI
BBG0027NWBR8
Share class FIGI
BBG0027NWBS7
LEI
549300EZ2NYFK7H0US48
EIN
27-5411038

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christopher M. HallChief Executive Officer, Director199,415
Richard ChenPresident and CMO169,882
Stephen Michael MooreSVP and Chief Legal Officer90,257
Aaron TachibanaCFO AND COO195,902
Karin EasthamDirector19,756
Lonnie ShoffDirector37,190
A. Blaine BowmanDirector19,756
Olivia Kyusuk BloomDirector27,265
Woodrow A. Myers JrDirector32,366
Kenneth J. WidderDirector6,250

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.51M$7.60M$1.60M$402–
FY2024$1.54M$4.41M$1.00M$292–
FY2023
Aaron Tachibana
$1.67M$1.40M$975.89K$106–
FY2023
Christopher Hall
$1.73M$1.40M$975.89K$106–
FY2022
Aaron Tachibana
$676.01K-$2.21M$951.54K$14–
FY2022
John West
$5.62M-$2.30M$951.54K$14–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Christopher Hall
Chief Executive Officer and Director
$618.00K$853.05K$1.78M$247.20K$3.00K$3.51M+128%
Aaron Tachibana
Chief Financial Officer and Chief Operating Officer
$545.90K$272.25K$656.15K$131.00K$3.00K$1.61M+59%
Richard Chen, M.D., M.S.
President, Executive Vice President, Research and Development and Chief Medical Officer
$530.45K$272.25K$656.15K$127.30K$3.00K$1.59M+61%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 20, 2019
Offer price
$17.00
Securities offered
7,921,500
Gross proceeds
$134.67M
Exchange
Nasdaq
First trading day
Jun 20, 2019
First-day close
$28.49+67.6%
Lock-up ends (est.)
Dec 17, 2019

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of January 31, 2026, we had 260 employees, of which 259 were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?